(n=49) 103.3sirtuininhibitor5.5 (n=33) 87.5sirtuininhibitor3.2 (n=63) five.25sirtuininhibitor.94 (n=52) ten.6sirtuininhibitor.9 (n=46) two.25sirtuininhibitor.9 (n

(n=49) 103.3sirtuininhibitor5.5 (n=33) 87.5sirtuininhibitor3.2 (n=63) 5.25sirtuininhibitor.94 (n=52) ten.6sirtuininhibitor.9 (n=46) 2.25sirtuininhibitor.9 (n=46) 191.3sirtuininhibitor5.8 (n=67) 55.9sirtuininhibitor1.two (n=64) 122.1sirtuininhibitor4.four (n=64) 129.1sirtuininhibitor7.4 (n=64) 167.2sirtuininhibitor8.0 (n=34) 0.94sirtuininhibitor.eight (n=34) two.47sirtuininhibitor.7 (n=34) 26.5sirtuininhibitor4.7 (n=34) 39.8sirtuininhibitor8.two (n=34) BSM-treated…

Sduringthemetabolicstudy.Hyperlipidemicsubjectsoftenhave delayedLDLapoB-100catabolism(seesupplementalTable S3).Wehavedocumentedalsothatfeedingresultsinmore directTRLapoB-100catabolismandlessconversionofTRL apoB-100toLDLapoB-

Sduringthemetabolicstudy.Hyperlipidemicsubjectsoftenhave delayedLDLapoB-100catabolism(seesupplementalTable S3).Wehavedocumentedalsothatfeedingresultsinmore directTRLapoB-100catabolismandlessconversionofTRL apoB-100toLDLapoB-100,aswellasdelayedLDLapoB-100 catabolism,comparedwiththefastingstate(29).In spite of thedifferences,ourfindingsareconsistentwiththesepreviousstudiesandsupporttheconceptthatapoBinsdLDLs iscatabolizedmoreslowlythanapoBinlbLDLs. Our data indicate that approximately 80 of lbLDL apoB-100isderivedfromTRLapoB-100,withtheremainderMetabolism and proteomics of LDL subfractionsTABLE three. ApolipoproteincompositionoflbLDLandsdLDLduringplaceboandtreatmentwithrosuvastatin40mg/dayPlacebo(totalproteinspectralintensity,logbase2) Proteins lbLDL sdLDL PbRosuvastatin(totalproteinspectralintensity,logbase2)…

IL-6R -Actin Forward primer ATGGAAGAGAC Transthyretin/TTR Protein Biological Activity CTTCAGCTAC GGAATCTTGGA GCGAGTTGT TGCAAAGCTATA GGTGGAGAGCIL-6R -Actin

IL-6R -Actin Forward primer ATGGAAGAGAC Transthyretin/TTR Protein Biological Activity CTTCAGCTAC GGAATCTTGGA GCGAGTTGT TGCAAAGCTATA GGTGGAGAGCIL-6R -Actin Forward primer ATGGAAGAGAC CTTCAGCTAC GGAATCTTGGA GCGAGTTGT TGCAAAGCTATA GGTGGAGAGC AGTTGCCTTCTT GGGACTGA TCATTCAGAGCC AGCTGCCCAT CAAGCCTTTCC TGACAGAGG CATCTGAACCG…

ESNP locationPCR amplification primer sequence (5' ?3') aGccatcGat aGtcGaaacG taGGcacGaat ttGcttGaa tccaaGcGta tGctcaaGaa GcacaataGc GaGatGGtca

ESNP locationPCR amplification primer sequence (5' ?3') aGccatcGat aGtcGaaacG taGGcacGaat ttGcttGaa tccaaGcGta tGctcaaGaa GcacaataGc GaGatGGtca taatcctGGcG atGaGatcc tttGccaaGc tcctccatac GaacctcGca tGGttGaGat aGGGcacttG GttccaGata GctcatcaGG cttttGGaaG GcacaaGcca cccactattt GctcatcaGG cttttGGaaG GcacaaGcca…